Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cabio Biotech (Wuhan) Co's quarterly market cap
declined
from Sep. 2025 (¥4,300.3 Mil) to Dec. 2025 (¥3,918.2 Mil) and
declined
from Dec. 2025 (¥3,918.2 Mil) to Mar. 2026 (¥3,029.6 Mil).
Cabio Biotech (Wuhan) Co's annual market cap
increased
from Dec. 2023 (¥3,012.7 Mil) to Dec. 2024 (¥3,202.9 Mil) and
increased
from Dec. 2024 (¥3,202.9 Mil) to Dec. 2025 (¥3,918.2 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Cabio Biotech (Wuhan) Co's Enterprise Value for Today is ¥1,613.5 Mil.
Cabio Biotech (Wuhan) Co (SHSE:688089) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Cabio Biotech (Wuhan) Co Market Cap Related Terms
Cabio Biotech (Wuhan) Co Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688089 vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Cabio Biotech (Wuhan) Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cabio Biotech (Wuhan) Co Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cabio Biotech (Wuhan) Co's Market Cap distribution charts can be found below:
* The bar in red indicates where Cabio Biotech (Wuhan) Co's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Cabio Biotech (Wuhan) Co's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cabio Biotech (Wuhan) Co (SHSE:688089) has a Market Cap of ¥1,785.8 Mil as of Jul. 19, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Cabio Biotech (Wuhan) Co and its competitors. According to the industry distribution chart, Cabio Biotech (Wuhan) Co ranks #542 out of 1424 companies in the Biotechnology industry, placing it in the top 38.1%.
Is Cabio Biotech (Wuhan) Co's Market Cap too high?
Cabio Biotech (Wuhan) Co's current Market Cap is ¥1,785.8 Mil. Based on the distribution chart, Cabio Biotech (Wuhan) Co ranks #542 out of 1424 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Cabio Biotech (Wuhan) Co has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cabio Biotech (Wuhan) Co's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cabio Biotech (Wuhan) Co ranks #542 out of 1424 companies for Market Cap. This puts Cabio Biotech (Wuhan) Co in the upper half of its industry. The industry median Market Cap is 112.84. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 112.84, based on 1,424 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Cabio Biotech (Wuhan) Co and its competitors. For the Biotechnology industry, the median Market Cap is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cabio Biotech (Wuhan) Co's current Market Cap is ¥1,785.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cabio Biotech (Wuhan) Co stock overvalued right now?
Based on GuruFocus' analysis, Cabio Biotech (Wuhan) Co (SHSE:688089) is currently considered Possible Value Trap. The stock's GF Value™ is ¥20.66, compared to a current price of ¥10.61 — trading 48.6% below its estimated fair value. The current Market Cap is ¥1,785.8 Mil. Cabio Biotech (Wuhan) Co's overall GF Score™ is 67/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Cabio Biotech (Wuhan) Co (SHSE:688089), the current Market Cap is ¥1,785.8 Mil as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cabio Biotech (Wuhan) Co (SHSE:688089) Overvalued in 2026?
Based on GuruFocus' analysis, Cabio Biotech (Wuhan) Co stock appears to be undervalued.
The current stock price of ¥10.61 is trading 48.6% below its estimated GF Value™ of ¥20.66.
GuruFocus considers Cabio Biotech (Wuhan) Co to be Possible Value Trap.
Key valuation signals for SHSE:688089:
Market Cap: ¥1,785.8 Mil
GF Value™: ¥20.66 vs. price of ¥10.61 (48.6% below fair value)
No single metric tells the full story. See the SHSE:688089 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cabio Biotech (Wuhan) Co Ltd is a biotechnology company, engaged in Research & Development, production and sales of polyunsaturated fatty acids ARA, algae oil DHA and SA, natural B-carotene and other series products. The products are used in infant formula, dietary nutrition supplements and health Food, special medical formula food and other fields. The company's product sales area covers China, the United States, Europe, Australia, New Zealand, South Korea, and Southeast Asia.
67GF Score
Get the complete analysis for SHSE:688089
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688089 has been successfully added to your 
